Prescient Therapeutics Limited

ASX:PTX Stock Report

Market Cap: AU$33.0m

Prescient Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Prescient Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-0.06%

Buyback Yield

Total Shareholder Yield-0.06%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Jul 05
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth

Mar 12
We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth

We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate

Nov 14
We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate

Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth

Aug 01
Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth

Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Nov 22
Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Oct 19
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Jun 19
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Feb 27
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now

Nov 05
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now

We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

Aug 26
We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

May 08
Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

Jan 11
Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if PTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTX's dividend payments have been increasing.


Dividend Yield vs Market

Prescient Therapeutics Dividend Yield vs Market
How does PTX dividend yield compare to the market?
SegmentDividend Yield
Company (PTX)n/a
Market Bottom 25% (AU)2.6%
Market Top 25% (AU)6.2%
Industry Average (Biotechs)2.4%
Analyst forecast (PTX) (up to 3 years)n/a

Notable Dividend: Unable to evaluate PTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate PTX's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PTX has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 20:11
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Prescient Therapeutics Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paul HickmanEdison Investment Research
Joseph PantginisH.C. Wainwright & Co.